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Processes similar to endochondral or intramembranous bone
formation occur in the vascular wall. Bone and cartilage
tissue as well as osteoblast- and chondrocyte-like cells are
present in calcified arteries. As in bone formation, apoptosis
and matrix vesicles play an important role in the initiation of
vascular calcification. Recent evidence indicates that
nanocrystals initially formed in the vessel wall may actively
be involved in the progression of the calcification process.
This review focuses on the cellular and structural similarities
between bone formation and vascular calcification and
discusses the initial events in this pathological mineralization
process.
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Vascular calcification is a well-defined risk factor for cardiovas-
cular disease and mortality.1–3 Patients with chronic kidney
disease (CKD) are susceptible to the onset and progression of
calcification in the arteries. The more the kidney function
declines, the greater the risk to develop vascular calcification.4,5
Intimal calcification of atherosclerotic lesions is more frequently
and severely present in CKD stage 4/5 compared with earlier
stages and people with normal renal function.4,6 Although seen
with aging, calcification of the tunica media occurs rarely in the
normal population; however it develops distinctively in CKD
patients6,7 and diabetics.8 Moreover, the prevalence and progres-
sion of vascular calcification dramatically accrues once patients
enter end-stage renal disease and require dialysis treatment.4,9–11
Apart from traditional risk factors such as age, hyperten-
sion, and dyslipidema, a disturbed mineral metabolism
contributes to the high calcification burden in the arteries
of CKD patients. Increased circulating amounts of both
calcium and phosphate, the two components of bone
mineral, are associated with the development of vascular
calcification.12–14 At the cellular level also, calcium and
phosphate have been shown to stimulate differentiation of
vascular smooth muscle cell toward calcifying cell types that
normally only appear in bone tissue.15,16 In addition to the
presence of promoters of the calcification process, CKD is
characterized by decreased concentrations of circulating
inhibitors. Low levels of fetuin-A and pyrophosphate in
dialysis patients are associated with arterial calcification,17,18
whereas increased levels of the inactive uncarboxylated form
of matrix Gla protein found in CKD 4/5 correlate with the
severity of vascular calcification.19
This review mainly focuses on the cellular and molecular
mechanisms underlying vascular calcification in comparison
with physiological bone formation, in particular in the
setting of CKD. These pathophysiological mechanisms also
contribute to calcemic uremic arteriolopathy, a distinct form
of medial calcification of the cutaneous vessels that causes
necrotizing skin lesions and is associated with very high
mortality rates, and to the calcification of native and
bioprosthetic cardiac valve leaflets.
BONE REMODELING IN THE VESSEL WALL
Intramembranous and endochondral bone formation
Bone develops by two different processes, either directly
through conversion of connective tissue into bone, known as
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intramembranous bone formation, or indirectly through the
replacement of an initially formed cartilaginous matrix by
bone, which is termed endochondral bone formation. In both
processes, osteoblasts play a central role in the production
and mineralization of the extracellular bone matrix.
Intramembranous bone formation starts with the con-
densation of mesenchymal cells under the influence of local
factors, such as fibroblast growth factors and bone morpho-
genetic proteins, in a highly vascularized area of the embryonic
connective tissue. The mesenchymal cells subsequently prolifer-
ate and differentiate directly into preosteoblasts and osteoblasts,
which secrete the organic extracellular bone matrix. The trans-
cription factors cbfa1 (core binding factor a1) and osterix (osx)
play an important role in the regulation of this differentiation
process. Osx is specific to osteoblasts and is required for the
differentiation of preosteoblasts to mature osteoblasts. As osx
is not expressed in cbfa1 knockout mice whereas cbfa1 is
expressed in mice lacking the osx gene, osx is considered a
downstream gene of cbfa1.20 Mesenchymal cells of osx-null
mutant mice that still express cbfa1 are arrested in the
differentiation toward osteoblasts and acquire a chondrocyte
phenotype with expression of sex determining region Y-box 9
(sox9), collagen II, and Indian hedgehog.20 Recently, it has
been reported that osx also exhibits osteoblastic activity
independently of cbfa1: osx overexpression in cbfa1-deficient
cells indeed induced alkaline phosphatase activity and
expression of osteocalcin and bone sialoprotein.21 Cbfa1
directly regulates the expression of osteoblast-specific genes
such as osteocalcin, osteonectin, and osteopontin.22 Osteo-
genic differentiation initially is characterized by the expres-
sion of alkaline phosphatase followed by the synthesis and
deposition of collagen I and glycosaminoglycans, the bone
matrix proteins playing an essential role in the mechanical
properties of bone. In addition, bone matrix also contains
osteopontin and bone sialoprotein that may contribute to the
initiation of the mineralization process through their
calcium-binding capacity.23 Membrane-bound extracellular
matrix vesicles released from osteoblasts are involved in the
mineralization of the bone matrix and can facilitate the
initiation of this process by accumulating calcium and
phosphate ions in a protected environment.24,25 Crystals
accumulate and grow in the vesicles, deposited on the
collagen matrix, until the rigid hydroxyapatite crystals
perforate the vesicle bilayer. Extravesicular crystals then start
proliferating rapidly and, as bone matures, crystals become
larger and finally will aggregate.26 Part of the osteoblasts will
ultimately be embedded in the calcified bone matrix and
become osteocytes.27,28
Conversely, endochondral bone formation is characterized
by the formation of a cartilaginous template that in a later
stage is degraded and replaced by bone. During this process,
mesenchymal cells proliferate and differentiate into chon-
droblasts that produce cartilage matrix rich in collagen,
fibronectin, and hyaluronan.29 In the growth plate, chon-
drocytes appear in regular columns, each derived from a
single chondroblast, and different zones are distinguished in
the cartilage, an organization required for long bone
elongation. Chondroblasts become rounded chondrocytes
that secrete collagen IX, XI, and mainly II, along with Gla
proteins and aggrecan.29 The transcription factor sox9 plays a
crucial regulator in the early phase of the chondrocyte
differentiation pathway.30,31 It regulates the conversion of
mesenchymal cells to chondroprogenitors and the establish-
ment of the chondrogenic mesenchymal condensations
during endochondral bone formation, and promotes the
expression of downstream proteins such as collagen II.
Chondrocyte proliferation allows bone elongation, and
during the subsequent differentiation phase chondrocytes
enlarge progressively, become hypertrophic, produce collagen
X, and start the mineralization process of the cartilage
matrix. Hypertrophic chondrocytes produce vascular en-
dothelial growth factor, which attracts blood vessels to the
primary ossification center.32 At this terminal chondrocyte
differentiation stage, cbfa1 is highly expressed, thereby
priming hypertrophic chondrocytes to undergo apoptosis.
Angiogenesis permits degradation of the cartilage. The vessels
recruit osteoclasts, which degrade the cartilage by secreting
factors such as matrix metalloproteinase 9, as well as
osteogenic cells that differentiate into osteoblasts. Osteoblasts
in turn deposit bone matrix on the cartilage remainder,
resulting in the complete replacement of the cartilage
template by trabecular bone.27,28
Physiological versus pathological mineralization
Under physiological conditions, extracellular matrix miner-
alization occurs in bone and teeth, whereas other tissues seem
to be protected from matrix mineralization. The molecular
mechanisms contributing to physiological matrix mineraliza-
tion are not fully elucidated. Murshed et al.,33 however, based
on an elegant series of experiments tried to explain the spatial
restriction of physiological mineralization in bone and teeth
using various mutant mice strains. This group found that
ANK (multipass transmembrane protein) and ectonucleotide
pyrophosphatase phosphodiesterase (Enpp1), which regulate
extracellular pyrophosphate concentrations, are expressed in
almost every tissue, indicating that a general calcification
inhibitor must prevent pathological calcification. In osteoblasts,
alkaline phosphatase is highly expressed and is responsible for
the degradation of pyrophosphate allowing mineralization of
the bone matrix. However, alkaline phosphatase activity alone is
not sufficient for matrix mineralization as this enzyme is also
highly expressed in liver and kidneys, organs that under normal
physiological conditions do not mineralize. Using different
transfected cell lines, Murshed et al.33 demonstrated that an
additional condition needs to be accomplished, that is, the
presence of a fibrillar collagen-rich matrix as a scaffold on which
hydroxyapatite crystals can be deposited. Hence, coexpression of
alkaline phosphatase and collagen I is required for tissue bone
mineralization, and no mineralization takes place in either the
absence of alkaline phosphatase activity or lack of collagen I
expression in osteoblasts. Moreover, co-transfection of alkaline
phosphatase and collagen I in liver cells induced mineralization
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in the presence of b-glycerophosphate. These results are of
particular interest as osteoblasts and odontoblasts are the only
cell types in which both genes are coexpressed under physio-
logical conditions, explaining the spatial restriction of matrix
mineralization to bone and teeth.
The vascular tunica media is also composed of a collagen-
rich matrix with vascular smooth muscle cells. Normally,
these cells do not express alkaline phosphatase. However,
under calcifying uremic conditions, particularly increased
phosphate levels, alkaline phosphatase activity has been
reported in vascular smooth muscle cells.34–36 The finding
that a unique coexpression of alkaline phosphatase and
collagen is necessary for matrix mineralization adds a new
perspective to the comparison between physiological miner-
alization in bone and pathological calcification in the vessel
wall and provides a new target in the therapeutic manage-
ment of ectopic mineralization.
Evidence for mineralization-competent cells in the vessel wall
Evidence has been provided in literature that ectopic
calcification in the vessel wall closely reflects endochondral
and intramembranous bone formation. Cartilaginous tissue
has been reported to be associated with both intimal and
medial calcification in human arteries,37 and arteries of rats
with adenine-induced chronic renal failure38,39 and mice lacking
matrix Gla protein40 or PC-1/Enpp-1.41 Chondrocyte-like cells
in the vessel wall, identified by the expression of specific markers
such as sox9, collagen II and X, and morphologically resem-
bling hypertrophic chondrocytes in the growth plate, are
embedded in cartilage tissue that starts to calcify to form
bone. Although parallels are found with endochondral bone
formation, chondrocytes and cartilage are not consistently
found in calcified arteries, suggesting that direct calcification
of vascular tissue into bone-like tissue, as occurs during
intramembranous bone formation, also takes place during
arterial calcification. The structure of the mineral phase in
the vessel wall is mainly identified as hydroxyapatite, identical
to the mineral compound present in bone, which further
supports the concept that vascular calcification is not just a
passive deposition of amorphous calcium phosphate but
rather a cell-controlled process where osteoblast-like and
chondrocyte-like cells in the vessel wall are involved in the
formation of apatite crystals. The origin of the osteochon-
drogenic cells in arteries might be multiple. Using a cell
lineage mapping study in matrix Gla protein knockout mice,
the group of Giachelli42 has shown that 97% of the
chondrocyte-like cells in association with marked aortic
medial calcification had transdifferentiated from medial
smooth muscle cells in situ. In line with these findings, in
calcified intimal atherosclerotic plaques part of the chon-
drocyte-like cells, evidenced by sox9 expression, also
expressed a-smooth muscle actin, pointing toward vascular
smooth muscle cells as being the origin of these cartilage and
bone-forming cells.43 However, sox9-positive cells without
a-smooth muscle actin expression were also reported,
suggesting alternative sources of osteochondrogenic cells in
the vessels with this type of vascular calcification. Indeed, a
bone marrow transplantation study in low-density lipopro-
tein (LDL) receptor knockout mice, a well-characterized
diabetic experimental model with atherosclerotic intimal
calcification, has shown that the majority of chondrocyte-like
cells, colocalized with calcification, originate from bone
marrow precursor cell, particularly CD34þ /CD13þ myeloid
precursors.44 In this respect, it is worth mentioning that the
vascular adventitia acts as a reservoir for progenitors and
multipotent stem cells45 that might partly be delivered
through the vasa vasorum and may also undergo osteochon-
drogenic differentiation and contribute to the calcification
process in the arterial wall. Pericytes residing in the adventitia
are capable to differentiate in different cell types such as
osteoblasts and chondrocytes46,47 and have been reported to
be involved in vascular calcification.48 From the above
studies, calcification of the vascular media seems to go hand
in hand with local differentiation of vascular cells into bone
cells, whereas migration of remote precursor cells from the
bone marrow with subsequent activation toward osteochon-
drogenic cells is likely to play an important role in
calcification of atherosclerotic plaques. However, studies are
warranted to further examine whether the origin of the cells
involved in vascular calcification is correlated with the
type and thus the location of the calcification or rather is
determined by the underlying disease state with its
characteristic inducers of the calcification process.
Making a distinction between osteoblast and chondrocyte
differentiation in the arteries is not always easy, as both
cell types share several common markers such as alkaline
phosphatase, osteocalcin, osteopontin, osteonectin, and bone
sialoprotein.49,50 More importantly, cbfa1, mostly regarded as
a specific marker of the osteoblast differentiation pathway, is
also responsible for terminal differentiation in chondrocytes
and is highly expressed by hypertrophic chondrocytes.50
From cell culture experiments, it is clear that vascular smooth
muscle cells can undergo both osteoblast and chondrocyte
differentiation. Both osteogenic and chondrogenic potential
of calcifying vascular cells has been demonstrated in a
subpopulation of bovine aortic cells.51 When brought into
culture in medium without calcification stimulators, vascular
smooth muscle cells from normal human aortas express both
cbfa1 and sox9 mRNA, indicating the ability to undergo
chondrogenic differentiation.36 During skeletal embryogen-
esis, not only chondrocytes and osteoblasts, but also smooth
muscle cells develop from multipotent mesenchymal pre-
cursor cells, and the direction in which they are terminally
guided depends on the molecular pathways that are activated
by many paracrine and autocrine factors. Accordingly, in the
vessel wall, it is very likely that osteogenic as well as
chondrogenic reprogramming of vascular cells takes place
and contributes to the calcification process. In our labora-
tory, studies in rats with adenine-induced chronic renal
failure revealed compelling evidence for the presence of
chondrocytes in aortas with prominent media calcification.
Clear expressions of sox9, collagen II, and aggrecan were
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detected at both the protein and mRNA levels. Moreover,
specific osteoblast differentiation pathways were suppressed;
that is, expression of osx and factors regulating the wnt/b-
catenin pathway significantly decreased at the time the
calcification process in the aorta started to develop.39 Both
osx and the wnt/b-catenin signaling pathway are responsible
for the segregation of common osteochondroprogenitor cells
toward osteoblasts, whereas suppression of these latter
pathways and induction of the transcription factor sox9
guide these progenitor cells to chondrocytes.52,53 In line with
our findings, the expression of osx and wnt proteins was
absent and msh homeobox (msx) expression was down-
regulated in aortas with medial calcification from matrix Gla
protein-deficient mice that suggests that in this experimental
model, medial calcification also went along with suppression
of the osteoblast phenotype.42 Indeed, chondrocyte-like cells
with high expression of collagen II were detected in calcifying
matrix Gla protein/ vessels. In contrast, the aortas of
diabetic LDL receptor (LDLR) knockout mice with both
plaque and medial calcifications show increased expression of
msx2, wnt3a, wnt7a, and osteopontin, corresponding with
activation of an osteogenic program.54 In this context, the
recently discovered dual role of osteopontin in vascular
calcification is worth mentioning. Osteopontin is not only an
inhibitor of the calcification process,55,56 but this molecule
also acts a macrophage–chemotactic stimulus and together
with its fragments elicits proinflammatory properties, there-
by exacerbating the inflammatory response that could
enhance the propensity to intimal calcification.57 Treatment
with infliximab, a neutralizing antibody against tumor
necrosis factor-a (TNFa), prevents the induction of these
osteoblastic genes with a concomitant reduction in aortic
calcium content, probably indicating that this proinflamma-
tory component is involved in the transdifferentiation
process of vascular smooth muscle cells. In light of these
findings, it is plausible that the molecular mechanisms
underlying vascular calcification and the factors involved
herein differ depending on the underlying pathology. In this
respect, it would be interesting to further focus on and
compare the cell biological and molecular mechanisms in
calcified arteries of CKD patients, where hyperphosphatemia
and uremic toxins are important triggers, with those of
diabetic patients who are at a high risk for arterial
calcification because of their inflammatory state. Dialysis
patients are an interesting study group carrying a high
prevalence and incidence of arterial calcification and
subjected to a variety of risk factors, which will be explained
more in depth further on in this paper.
Regardless of whether chondrogenic or osteogenic lineage
programs become activated, both cell types are able to initiate
mineralization through matrix vesicles. Matrix vesicles are
involved in both endochondral and intramembranous
mineralization processes. In bone and cartilage, differentiated
hypertrophic chondrocytes and osteoblasts pinch off matrix
vesicles (diameter 20–200 nm) from the plasma membrane
after which they serve as primary mineralization sites in close
association with extracellular matrix. Under pro-mineralizing
conditions, matrix vesicles excreted by chondrocytes are
bioactive, which means that they become mineralization
competent.58 Typically, alkaline phosphatase is strongly
expressed, creating high local availability of phosphate by
hydrolysis of organic phosphate substrates, hereby also
eliminating the calcification inhibitor pyrophosphate. This
dual action alters the phosphate/pyrophosphate ratio known
to be a critical determinant of matrix mineralization.33 Mice
deficient in tissue nonspecific alkaline phosphatase showed
that this enzyme mainly participates in the expansion and
growth of the preformed crystals in the matrix vesicles.59
Membrane type III Na/Pi co-transporters on the matrix
vesicle transport phosphate into the vesicles, and intracellular
phosphate concentrations inside these organelles are further
increased by the activity of the recently discovered cytosolic
phosphatases, called PHOSPHO1.60 Furthermore, annexin II,
V, and VI are abundantly expressed in calcifying matrix
vesicles where they serve as calcium channels to mediate
calcium influx for crystal growth. It has been shown that
collagen II and X, typically expressed by chondrocytes, bind
to annexin V thereby stimulating calcium transport in the
vesicles.61 Interestingly, this close interaction between matrix
vesicles with collagen structures as a requirement for matrix
mineralization was also found in bovine vascular smooth
muscle cells incubated with glycerophosphate.62
Calcifying vascular smooth muscle cells acquiring an
osteochondrogenic phenotype also release matrix vesicles
like osteoblasts and chondrocytes do during osteogenesis
(Figure 1). Under normal physiological conditions, human
vascular smooth muscle cells in vitro continuously release
small vesicles from the plasma membrane; however, after
exposure to calcium and phosphate, matrix vesicle release
was stimulated and in the absence of serum intra- and
extracellular vesicles contained preformed calcium phosphate
mineral within and on the surface of the vesicle.16 An
important finding was that matrix vesicles isolated from
vascular smooth muscle cells incubated with high phosphate
and calcium concentrations together with human serum
contained high levels of fetuin-A, explaining the reduced
calcification of cultured vascular cells in medium enriched
with serum. Matrix Gla protein was also highly concentrated
in vascular smooth muscle cell-derived vesicles. As such, a
natural defense mechanism against vascular calcification
exists in the vessel wall by circulating and local inhibitors,
even when high calcium and phosphate levels are around.
Reduced concentrations of calcification inhibitors in CKD
disturb the protective process of these proteins, thereby
facilitating crystal growth in matrix vesicles. In analogy with
hypertrophic chondrocytes from the growth plate under
mineralizing conditions,58 the components and activity of the
matrix vesicles formed by vascular smooth muscle cells
exposed to pro-calcifying conditions change compared with
nonmineralizing vascular cells in that the expression of
alkaline phosphatase and annexins was induced as well as the
calcium uptake, which markedly increased the vesicles’ ability
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to calcify collagen I (Figure 1).62 In advanced atherosclerotic
lesions of apolipoprotein E (apoE)-deficient mice, chondro-
cyte-like cells are closely associated with the presence of
vesicles, some of which contained needle-like structures.63
Matrix vesicle-like structures have also been identified in
human calcified arteries. Vesicles showing calcified deposits
were detected in the vicinity of chondrocyte-like cells in
human atherosclerotic plaques.43 Recent work in iliac
arteries64 and medium-sized muscular arteries65 presenting
medial calcifications obtained from dialysis patients confirm
the presence of vesicular structures in close proximity of
microcalcifications and collagen fibrils (Figure 1).
Are bone-resorbing cells involved in vascular calcification?
Although substantial evidence supports the presence of bone-
like cells capable to calcify vascular tissue, the involvement of
cells that potentially might resolve mineralization in the
vessel wall as seen during bone remodeling is more doubtful.
Few studies found multinucleated osteoclast-like cells in
calcified arteries from OPG (osteoprotegerin) knockout
mice66 or humans,67 based on the expression of the osteoclast
cell surface receptor receptor activator of nuclear factor
kB (RANK) and the osteoclast-specific proteins cathepsin K
and tartrate-resistant acid phosphatase. It is plausible that
osteoclast-like cells in calcified arteries originate from
circulating or locally present macrophages, particularly in
inflammation-driven vascular calcification, as both cell types
are derived from mononuclear precursors. As in normal bone
turnover, where RANK ligand secreted by osteoblasts induces
osteoclast differentiation and activation by binding on its
RANK receptor to stimulate bone resorption, high RANK
ligand expression by vascular cells in calcified vessels
might stimulate transdifferentiation of monocytes/macro-
phages into bone-resorbing cells. In this context, it is worth
mentioning that stimulation of RANK ligand expression
in murine aortic smooth muscle cells by protein kinase
A induced differentiation of RAW 264.7 cells from the
monocyte/macrophage line into osteoclasts.68 Alternatively,
osteoclast precursors attracted from bone marrow might
be involved as well. Bone marrow-derived osteoclasts are
capable to demineralize calcified aortic elastin in vitro and
in vivo.69 So far however, no clinical studies have reported
osteoclast-mediated regression of vascular calcification. One
experimental report has shown a 75% regression of vitamin
D-induced medial calcification at 9 weeks after withdrawal of
vitamin D.70 Macrophages were detected around calcified
areas that made the authors suggest ongoing resorption of the
deposited calcifications to be present. The arguments for
active resorption of vascular calcification are weak and more
studies dealing herewith are needed. Of interest, Speer et al.71
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have recently shown that cultured vascular smooth muscle
cells derived from matrix Gla knockout mice behave like
osteochondrogenic cells, but regain their smooth muscle cell
phenotype and loose the expression of osteochondrogenic
markers after 6 days when cultured in normal growth
medium. As such, the transdifferentiation of vascular cells
toward bone-forming cells is reversible, suggesting that
eliminating particular calcification triggers per se may event-
ually regress vascular calcification without the intervention of
bone-resorbing cells.
Role of apoptosis in mineralization
During endochondral bone formation, the majority of
hypertrophic chondrocytes in the growth plate terminate
their differentiation by apoptosis. It is believed that
chondrocyte apoptosis is not just a passive process, but plays
an active role in maintaining growth plate homeostasis,
vascular invasion, and matrix mineralization.72 Vesicles,
known as apoptotic bodies, bud from the membranes of
apoptotic chondrocytes and may serve as nucleators for
matrix mineralization and initiate replacement of cartilage by
bone. Similarly, in calcified aortas of uremic rats, some
morphologically distinguishable hypertrophic chondrocyte-
like cells embedded in cartilaginous tissue with initial
calcification spots were apoptotic that makes it not incon-
ceivable that at least part of the chondrocyte-like cells in the
vessel wall have a similar fate and role in the onset of vascular
calcification as chondrocytes do during bone development.38
At the chondro-osseous junction, calcified cartilage is
degraded by osteoclasts, thereby increasing the local con-
centration of calcium and phosphate. Both ions have been
shown to mediate apoptosis in terminally differentiated
chondrocytes.
Apoptosis has also been found to play a role in the onset
of vascular calcification (Figure 1). Vascular smooth muscle
cells exposed to calcium and phosphate in serum-free
medium undergo apoptosis, thereby initiating the calcifica-
tion process,16,73 possibly by downregulation of GAS6/Axl, a
signaling pathway known to protect from apoptotic death.73
Inhibition of apoptosis in vitro with the caspase inhibitor
ZVAD.fmk reduced calcification, whereas stimulation of cell
death accelerated the calcification process.74 Interestingly,
Ewence et al.75 reported that calcium phosphate micro- and
nano-crystals cause programmed cell death in human aortic
smooth muscle cells by rapidly increasing intracellular
calcium levels. Part of the cells displayed a rapid sustained
rise in intracellular calcium levels followed by loss of
membrane integrity as an indication of apoptosis, whereas
others recovered from the calcium rise toward baseline
values. Furthermore, it was shown that the small calcium
phosphate crystals are endocytosed by vascular cells and
degraded by lysosomal acidification, causing the intracellular
calcium rise.75 Studies on arterial specimens revealed that
arteries from dialysis patients exhibited significant apoptosis
and had a higher calcium load compared with predialysis
and control vessels.65 When cultured in high calcium and
phosphate medium, dialysis arteries displayed a marked
increase in apoptotic cells with simultaneous increase in
intracellular calcium load.76 Addition of ZVAD.fmk signifi-
cantly decreased the calcium load of dialysis vessels,
confirming the active role of cell death in the arterial
calcification. Yet, the active contribution of apoptosis in
arterial calcification in vivo was only recently recognized.
Using an animal model for atherosclerosis with chronic low-
grade induction of vascular smooth muscle apoptosis, Clarke
et al.77 demonstrated that chronic apoptosis promotes plaque
instability by fibrous cap thinning as well as intimal plaque
calcification. However, no effect of smooth muscle cell
apoptosis on medial calcification was detected, suggesting
that other triggers in the plaque environment had additional
effects on plaque calcification.
CRYSTAL FORMATION OR CELLULAR CONVERSION: WHAT
COMES FIRST?
Mineral deposits in the vascular wall physicochemically
mimic hydroxyapatite, the mineral structure of bone. Apatite
crystals are found as the main mineral phase formed in
calcified arteries in humans,64,75 rodents,78,79 and in cultured
medial smooth muscle cells,16,80 although whitlockite is also
observed in human and rat uremic arterial calcifications.64,79
Schlieper et al.64 characterized microcalcifications in the
vascular media of dialysis patients and found that these
aggregates have a core-shell structure and originate from
spherical nanocrystals (2–10 nm). Microcalcifications coloca-
lized with calcification inhibitors such as fetuin-A and matrix
Gla protein, which might be regarded as a (insufficient)
compensatory defense mechanism.
Recent studies highlight that nanocrystals, once formed,
actively participate in the expansion of the calcification
process (Figure 1). As mentioned above, these small crystals
are endocytosed by vascular cells and may force them to
undergo apoptosis, hereby contributing to matrix calcifica-
tion.75 In addition, nanocrystals activate the osteochondro-
genic program in vascular cells in vitro. The expression of
BMP-2 (bone morphogenetic protein 2) and osteopontin in
mouse aortic smooth muscle cells is induced by calcium
phosphate nanocrystals rather than phosphate ions alone.81
As a short-term effect of 24 h was studied in this experiment,
it would be interesting to investigate whether, in addition to
induction of apoptosis, nanocrystals are also able to induce
mineralization through stimulation of osteochondrogenic
conversion via more central and upstream players, such as
cbfa1, osterix, and sox9. Furthermore, the pathway by which
these nanocrystals mediate osteochondrogenic gene activity
remains an open question. Internalization and subsequent
acidification thereby increasing the ionic concentration of
intracellular phosphate and calcium which interact with gene
expression might be one possible mechanism. Alternatively,
calcium phosphate crystals trigger the uptake of other
molecules, for example, DNA plasmid, mainly by making
the cell more permeable.82 These findings suggest that uptake
of particular molecules from the extracellular milieu can be
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stimulated by nanocrystals that in turn may induce down-
stream effects at the level of gene expression.
The fact that nanocrystals themselves actively contribute
to the calcification process in different ways clearly adds a
new perspective on the mechanisms underlying vascular
calcification. Previously, it was believed that Pit1-mediated
uptake of calcium and particularly phosphate is the most
important trigger for the conversion of smooth muscle cells
toward mineralization-competent cells. Indeed, knockdown
of Pit1 in human aortic smooth muscle cells resulted in
decreased phosphate uptake and calcification and inhibition
of cbfa1 and osteopontin expression.83 Now that nanocrystals
have been identified as causal factors for the smooth muscle
cell phenotypic switch toward osteochondrogenic cells, the
question arises of whether smooth muscle cell conversion
precedes the formation of calcium phosphate deposits or
whether nanocrystals are initially formed in the extracellular
environment activating the osteochondrogenic transdiffer-
entiation cascade. In matrix Gla protein knockout arteries,
study of the temporal expression of osteochondrogenic
markers revealed that cbfa1 induction appeared before
the start of mineral deposition.42 In uremic rat aortas,
changes in gene expression profile occurred at the time
calcification was detected. Because light microscopic analysis
of Von Kossa-stained arterial sections, the most used
technique to observe development of vascular calcification,
is not sensitive enough to detect nanocrystal formation, the
sequential events underlying vessel calcification are difficult
to follow. A very important finding was published by
Speer et al.71 in that knockdown of cbfa1 in mouse vascular
smooth muscle cells in vitro led to a complete inhibition
of phosphate-induced matrix mineralization. Similarly,
inhibition of cbfa1 by short hairpin RNA blocked calcifica-
tion of vascular smooth muscle exposed to oxidative
stress.84 Thus, inhibition of calcification by blockage of the
transcriptional activity of one of the central players in
the osteogenic pathway indicates that transdifferentiation of
cells regulates pathological calcification. In the future, it
would be relevant to investigate whether blocking sox9, cbfa1,
and osx has an impact on the development of vascular
calcification in vivo. Targeting the calcification process at the
molecular level opens new opportunities for treatment,
particularly because in most syndromes a whole range of
provocative factors are involved that makes current ther-
apeutic strategies often inadequate. However, despite the
chicken or the egg dilemma in arterial calcification, once
mineralization is started, a vicious circle of osteochondro-
genic smooth muscle cell conversion and apatite formation is
maintained. Even when cellular activation might be initially
required before crystals are actually produced, the first
nanocrystals formed, originating from matrix vesicles and/or
apoptotic bodies, may be able to start the osteochondrogenic
reprogramming in neighboring vascular cells. Applied to the
clinical situation, the fact that small vascular deposits
themselves may reinforce the cellular calcification process is
not unimportant, assuming that patients suffering from
arterial calcifications, although mild, are prone to rapid
progression of this harmful process.
New molecular imaging techniques are promising tools to
follow the spatial and temporal evolution of the successive
stages in the development of vascular calcification.85,86
Intravital multichannel high-resolution laser scanning fluor-
escence microscopy was used to simultaneously monitor
inflammation and osteogenesis in atherosclerotic lesions of
apoE-deficient mice.86 Specific molecular imaging agents
target macrophages and osteogenic activity that can be
visualized in vivo. These modalities are able to map early
changes at the cellular and molecular levels in vivo in
atherosclerotic and medial calcification and will hopefully
help to discover the main targets for intervention.
DIALYSIS PATIENTS AT HIGH RISK FOR RAPID PROGRESSION
OF VASCULAR CALCIFICATION
Several clinical studies have reported a positive association
between vascular calcification and time on dialysis.9,11
Intimal plaque calcification is more frequent and severe in
hemodialysis patients than in patients suffering from earlier
CKD stages, and medial calcification was only detected in
CKD 4/5 and hemodialysis patients.4 The assertion that
dialysis in itself holds a risk for vascular calcification was
recently underscored by Shroff et al.76 Strikingly, vessels from
dialysis patients exposed to high calcium and phosphate
levels for up to 21 days showed a time-dependent increase in
calcium content, whereas healthy or predialysis vessels did
not, or at least to a much lesser extent. These results indicate
that dialysis treatment, upon the uremic milieu also present
in predialysis patients, primes arteries to develop vascular
calcification. The question remains: which factors make
dialysis patients susceptible for rapid progressive vascular
calcification?
In early stages of CKD, phosphate clearance is disturbed
because of kidney failure; however, serum phosphate levels
are kept under control, mainly by fibroblast growth factor-23
(FGF23) that maintains phosphate homeostasis by regulating
renal phosphate excretion. When the estimated glomerular
filtration rate decreases to o20ml/min per 1.73m2, repre-
senting CKD stage 4/5, the damaged kidney has no longer the
capacity to excrete sufficient phosphate and there is no
phosphaturic response in spite of high FGF23 levels, resulting
in phosphate retention, and hence increased serum phos-
phate concentration ensues.87 FGF23 and its cofactor Klotho
play an important role in vascular calcification. FGF-deficient
mice88,89 and mice deficient in Klotho90 exhibit extensive
vascular and soft tissue calcification. Serum FGF23, increased
in CKD, is shown to be associated with vascular calcifica-
tion.91 Interestingly, it was recently published that mice with
CKD had lower renal, plasma, and urinary levels of Klotho,
and a gradual decrease of urinary Klotho levels was observed
in humans with different degrees of renal failure.92 The role
of Klotho in vascular calcification was further underscored by
the fact that in addition to increasing the phosphaturia and
preserving glomerular filtration, Klotho inhibited smooth
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muscle cell mineralization in vitro by suppressing the Naþ -
dependent uptake of phosphate.92 Hyperphosphatemia worsens
in end-stage renal disease patients without residual renal function,
requiring dialysis treatment. The importance of phosphate
as a major promoter of vascular calcification is well known
and evidenced by clinical studies showing an association
between serum phosphate and arterial calcification,9,12,14,93
and by cell culture experiments demonstrating that phos-
phate contributes to the phenotypic change of vascular cells
with induction of mineralization.15,94 In addition, adenine-
induced chronic renal failure rats develop moderate-to-severe
medial calcifications when fed a high phosphorus diet.38
The role of hyperphosphatemia was also clearly demon-
strated in Klotho and sodium-phosphate type IIa transporter
double-knockout mice with low-to-normal serum phosphate
but high serum calcium and vitamin D levels showing
minimal vascular calcification versus Klotho knockout mice
with high serum phosphate, calcium, and vitamin D levels
exhibiting extensive vascular calcification.95 Despite phos-
phate clearance by dialysis and treatment with phosphate-
binding agents, serum phosphate increases between dialysis
sessions, which holds a risk for vascular calcification.12
A major factor that differentiates predialysis from dialysis
condition is the sustained calcium load. Patients with CKD
3–5 not in dialysis are more likely to be in a negative calcium
balance, particularly reflected by hypocalciuria and/or the
tendency to hypocalcemia, because of the inhibiting effect of
increased FGF23 levels on the production of active vitamin D
in the proximal tubule, and hence less absorption of calcium
at the level of the gut. The relative hypocalcemia combined
with phosphate retention are the main triggers for the
development of secondary hyperparathyroidism and high
bone turnover disease. However, when patients enter the
dialysis stage, a shift toward a positive calcium balance often
occurs. First, calcium loading arises from the dialysate per se,
and particularly during peritoneal dialysis, calcium concen-
trations of 2.5–3.0mEq/l are frequently used (of note, serum
ionized calcium levels are 1.8–2.5mEq/l). Increasing the
dialysate calcium concentration from 1.25 toward 1.75mmol/l
increased the pulse wave velocity after 6 months, indicating that
arteries become stiffer by calcium loading.96 Second, dialysis
patients are treated with phosphate-binding agents as standard
therapy to control hyperphosphatemia. Calcium containing
phosphate binders are commonly used, often in combination
with vitamin D to control secondary hyperparathyroidism,
thereby stimulating intestinal calcium absorption. Some studies
have reported an association between the use of calcium
phosphate binders and the progression of vascular calcification
in dialysis patients.97,98 Nevertheless, it should be noticed that
the use of noncalcium phosphate binders also increases serum
calcium concentrations.99 Strong intestinal phosphate binding
per se increases intestinal calcium absorption because of the
availability of free calcium ions in the gut. As no residual renal
function is left in patients with end-stage renal disease, the body
cannot get rid of the higher calcium intake, eventually resulting
in calcium loading.
Vascular calcification has been associated with calcium
intake.4,9,100 Interestingly, in vitro data accentuate the crucial
role of calcium in aortic mineralization.101 Cultured aortas
exposed to varying concentrations of calcium and phosphate
with calcium phosphate product kept constant showed that
calcification requires both ions, but that calcium rather than
phosphate is the dominant determinant.102 The predominant
role of calcium over phosphate in calcification was also
demonstrated in cultured fixed vascular smooth muscle
cells.103 Similar experiments in predialysis and dialysis vessels
revealed that for a fixed calcium phosphate product, higher
calcium concentrations were more potent to induce calcifica-
tion compared with higher phosphate levels.76 Furthermore,
clinical studies have shown that the calcium load aggravates if
bone turnover is suppressed, as the bone is not capable to
incorporate calcium.104 Oversuppression of parathyroid
hormone (PTH) may lead to adynamic bone. DOPPS I and
II studies show that up to 50% of hemodialysis patients
display low PTH levels, defined as o150 pg/ml, which make
them susceptible for adynamic bone disease.105 Extensive
arterial calcification was associated with low serum PTH
levels, low osteoblast surfaces, and low osteoclast number, the
characteristics for low bone activity and adynamic bone.106
The dosage of calcium containing phosphate binders was
strongly associated with aorta calcification and aortic
stiffness in end-stage renal disease patients with adynamic
bone.100 With regard to the role of the bone status in
vascular calcification, it is important to mention that besides
decreased bone formation and thus low bone turnover,
increased bone resorption also leads to vascular calcification.
Vitamin D exerts dual anabolic and catabolic effects on bone:
low doses of vitamin D have an anabolic effect, whereas
supraphysiological doses of this hormone stimulate bone
resorption.107 In line with this, the involvement of 1,25(OH)2
vitamin D3 in the pathogenesis of vascular calcification
may be considered a biphasic process.108 Indeed, besides
1,25(OH)2 vitamin D3 excess, deficiency of this hormone
may contribute to arterial calcification as well, thus
indicating that vitamin D has a dual role in the development
of vascular calcification, which might be explained by its
opposing anabolic and catabolic effects on bone.
An alternative strategy to lower PTH levels in dialysis
patients consists of the use of calcimimetics or vitamin D
analogs. Calcimimetics control PTH by activation of the
calcium-sensing receptor in the parathyroid gland, but in
contrast to vitamin D (calcitriol), these agents also reduce
serum calcium and phosphate levels in dialysis patients,
thereby reducing the risk for vascular calcification. Indeed,
experimental studies have shown that calcimimetic agents
reduce plaque and nonplaque calcification.109,110 In addition,
calcimimetics have been shown to exert anabolic effects on
bone in rats exhibiting low bone turnover,111 probably by the
induction of oscillating effects on PTH, which may represent
another mechanism by which these agents reduce vascular
calcification. New vitamin D analogs are able to suppress
serum PTH, but exhibit a reduced tendency to develop
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hypercalcemia when compared with calcitriol. A study
comparing the effect of different vitamin D receptor
activators on aortic calcification in uremic rats showed that
calcitriol and doxercalciferol increased the serum calcium
 phosphate levels and aortic calcium content, whereas
paricalcitol did not. Calcitriol and doxercalciferol treat-
ment also increased mRNA and protein expression of the
osteogenic markers cbfa1 and osteocalcin in the aorta,
whereas paricalcitol did not alter the expression of these
proteins.112 Similarly, low doses of paricalcitol protect
against vascular calcification in the atherosclerotic high-fat-fed
ldlr/ mouse through the inhibition of the expression of
osteoblast genes.113 However, to what extent calcimimetics
and calcitriol analogs are more effective in preventing or
retarding the progression of vascular calcifications than the
current treatment strategies still needs to be investigated in
clinical trials.
Finally, dialysis treatment is characterized by a state of
chronic inflammation,114 which has also been identified as a
risk factor for vascular calcification. Serum C-reactive protein
concentrations and the proinflammatory cytokine interleu-
kin-6 strongly correlate with coronary calcium scores.115–117
In hemodialysis patients, the C-reactive protein level was
found to be a significant predictor for calcification in the
aorta and peripheral arteries.118 The proinflammatory
cytokine TNF-a is another inflammation marker upregulated
in end-stage renal disease patients. Calcifying vascular cells
(a cloned subpopulation of bovine aortic smooth muscle cells
prone to mineralization in vitro) incubated with TNF-a
showed a dose-dependent increase in calcium deposition.119
TNF-a also enhances the expression of cbfa1, osx, alkaline
phosphatase, and bone sialoprotein in human vascular
smooth muscle cells exposed to calcification medium.120
In vivo evidence for the role of TNF-a in vascular calcification
comes from the study of Al-Aly et al.:54 treatment of LDLR
knockout mice with infliximab, a monoclonal antibody against
TNF-a, decreases medial calcification and inhibits osteogenic
differentiation of vascular cells.
In summary, in addition to phosphorus, dialysis patients
are often exposed to a positive calcium balance and inflam-
matory factors. As these parameters are crucial risk factors
for the development and progression of vascular calcification,
they should be controlled more rigorously.
CONCLUSION
In vivo and in vitro studies have converged to our current
knowledge on the cell biological and physicochemical aspects
of vascular calcification, a mechanism showing striking
similarities to physiological bone formation. Similar to
osteoblasts in bone, the bone-forming cells in the vessel wall
are able to release matrix vesicles in which immature calcium
phosphate crystals are formed. Nanocrystals can be endocy-
tosed by vascular cells and are able to induce apoptotic cell
death or activate an osteogenic program in vascular smooth
muscle cells, both of which are known processes in the
initiation of vascular calcification. These findings raise the
question of whether nanocrystal formation precedes osteo-
chondrogenic conversion of vascular cells or vice versa and
whether these small calcium phosphate deposits themselves
stimulate vascular cells to release matrix vesicles which in turn
may act as nucleation points for further crystal formation.
Therefore, in terms of future therapeutic strategies, it will be
highly relevant to further investigate the initial and sequential
steps in arterial calcification, particularly whether blocking
cellular conversion toward bone-forming cells halts or retards
the calcification process in vivo.
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